Physician profile
John G Allred
NPI 1336136977
$2,168.38
in general payments reported to CMS, 2019-2025
33 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $265 · 2021: $426 · 2022: $419 · 2023: $386 · 2024: $158 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $708.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $164.04 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $156.36 | 2020-2024 | Vaxelis, Gardasil 9, Rotateq |
| Abbott Laboratories | $134.04 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Dynavax Technologies Corporation | $121.00 | 2019-2025 | Heplisav-B |
| Amgen INC. | $115.50 | 2019-2020 | |
| Glaxosmithkline, LLC. | $115.43 | 2019-2025 | Shingrix, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $100.92 | 2022 | |
| Sanofi Pasteur INC. | $100.38 | 2019-2023 | |
| Amarin Pharma, INC. | $97.45 | 2020-2021 | |
| Genentech USA, INC. | $95.46 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $93.27 | 2019-2025 | Spravato |
| Astrazeneca Pharmaceuticals LP | $91.69 | 2019-2023 | Flumist Quadrivalent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.80 | 2019-2021 | |
| Cranial Technologies, INC | $80.40 | 2019-2025 | Doc Band |
| Organon LLC | $69.20 | 2022-2025 | Nexplanon |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $66.51 | 2019-2023 | |
| Novo Nordisk INC | $52.44 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $49.40 | 2021 | |
| Pfizer INC. | $45.58 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.77 | 2021-2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $42.53 | 2025 | |
| Lucid Diagnostics INC. | $31.80 | 2022 | |
| Qiagen, LLC | $28.58 | 2020 | |
| Ucb, INC. | $27.86 | 2022 | |
| Vanda Pharmaceuticals INC. | $26.20 | 2020 | |
| Eisai INC. | $23.97 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $20.14 | 2022 | |
| Baxter Healthcare | $18.44 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Abbvie INC. | $16.88 | 2022 | |
| Modernatx, INC. | $16.22 | 2023 | Moderna Covid-19 Vaccine |
| Boston Scientific Corporation | $14.54 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.29 | 2019 | |
| Shire North American Group INC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Allred listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.